On November 9, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported that it has entered into agreements to settle an aggregate of $235,908.60 in outstanding obligations through the issuance of common shares of the Company (the "Settlement Shares") at a deemed price of $0.175 per share, based on the closing price of the Company’s common shares on November 4, 2026 (the "Debt Settlement").
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Debt Settlement comprises $125,493.70 in accrued interest owing to holders of the Company’s existing 12.0% unsecured convertible debentures and $110,414.90 in outstanding amounts payable to certain service providers.
The issuance of the Settlement Shares remains subject to all requisite regulatory approvals, including approval of the TSX Venture Exchange (the "TSXV"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Stock Option Grant
The Company also announces that its board of directors has approved the grant of an aggregate of 124,000 stock options (the "Options") to certain directors and consultants pursuant to the Company’s Long-Term Incentive Plan.
The Options have an exercise price of $0.20 per common share, expire five years from the date of grant and vest in equal quarterly instalments over a one-year period.
(Press release, Rakovina Therapeutics, NOV 9, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-shares-for-debt-transaction [SID1234674486])